Cargando…

Preclinical Alzheimer’s disease: how to predict who will decline next year?

This scientific commentary refers to ‘Medial temporal tau predicts memory decline in cognitively unimpaired elderly’, by Kwan et al. (https://doi.org/10.1093/braincomms/fcac325).

Detalles Bibliográficos
Autores principales:	Hanseeuw, Bernard J, Johnson, Keith A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Scientific Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065177/ https://www.ncbi.nlm.nih.gov/pubmed/37006330 http://dx.doi.org/10.1093/braincomms/fcad079

Ejemplares similares

An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
por: Hardy, John, et al.
Publicado: (2023)

Putting the Brakes on Accelerated Cognitive Decline in Alzheimer’s Disease with Epileptic Activity
por: Vossel, Keith
Publicado: (2023)

Investigating cortico-striatal beta oscillations in Parkinson’s disease cognitive decline
por: Hnazaee, Mansoureh Fahimi, et al.
Publicado: (2023)

Sleep and future cognitive decline
por: Coulthard, Elizabeth, et al.
Publicado: (2021)

Preclinical Alzheimer's disease and longitudinal driving decline
por: Roe, Catherine M., et al.
Publicado: (2016)

Music, memory and mechanisms in Alzheimer’s disease
por: Clark, Camilla N., et al.
Publicado: (2015)

Concatenating plasma p-tau to Alzheimer’s disease
por: Tijms, Betty M, et al.
Publicado: (2021)

Alzheimer’s disease, cerebrovascular disease and dementia: lump, split or integrate?
por: Biessels, Geert Jan
Publicado: (2022)

Spouse-Appraised Memory Functioning Predicts Memory Decline Better Than Subjective Memory Complaints in Community Dwelling Older Adults at Genetic Risk for Alzheimer's Disease
por: Bellaali, Youssef, et al.
Publicado: (2021)

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2023)

Candesartan—the next anti-amyloid drug?
por: Yasar, Sevil
Publicado: (2022)

In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer’s disease
por: Toombs, Jamie, et al.
Publicado: (2020)

Detecting early changes in Alzheimer’s disease with graph theory
por: Pereira, Joana B
Publicado: (2020)

Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer’s disease
por: Hanseeuw, Bernard J., et al.
Publicado: (2019)

Is phosphorylated tau a good biomarker of synapse pathology in Alzheimer’s disease?
por: Saura, Carlos A, et al.
Publicado: (2023)

Targeting MCAM for next-generation modulation of leucocyte trafficking
por: Schneider-Hohendorf, Tilman, et al.
Publicado: (2023)

Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
por: Newby, Danielle
Publicado: (2022)

Predicting Alzheimer's risk: why and how?
por: Barnes, Deborah E, et al.
Publicado: (2011)

Determining clinically meaningful decline in preclinical Alzheimer disease
por: Insel, Philip S., et al.
Publicado: (2019)

Facilitating fluency in adults who stutter
por: Crinion, Jennifer T
Publicado: (2018)

Biological single-particle imaging using XFELs – towards the next resolution revolution
por: Oberthür, Dominik
Publicado: (2018)

Plasma p-tau217: from ‘new kid’ to most promising candidate for Alzheimer’s disease blood test
por: Teunissen, Charlotte E, et al.
Publicado: (2020)

Mosaic APP Gene Recombination in Alzheimer’s Disease—What’s Next?
por: Lee, Ming-Hsiang, et al.
Publicado: (2019)

The Charcot-Marie-Tooth diseases: how can we identify and develop novel therapeutic targets?
por: Roberts, Rhys C.
Publicado: (2012)

Mysteries of icosahedral quasicrystals: how are the atoms arranged?
por: Ishimasa, Tsutomu
Publicado: (2016)

How COVID-19 affects microvessels in the brain
por: Wenzel, Jan, et al.
Publicado: (2022)

Your nose knows how to target brain inflammation
por: Winger, Ryan C., et al.
Publicado: (2016)

How many tricks can an old perovskite play?
por: Kennedy, Brendan J.
Publicado: (2017)

Triosephosphate isomerase: the perfect enzyme, but how does it work?
por: Helliwell, John R.
Publicado: (2021)

Evaluating when (and how) hypertension may be ‘good for your brain’
por: Magaki, Shino D, et al.
Publicado: (2023)

Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease
por: Yu, Xianfeng, et al.
Publicado: (2023)

Cognitive Decline in Preclinical Alzheimer’s Disease: Amyloid-Beta versus Tauopathy
por: Huber, Colin M., et al.
Publicado: (2017)

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
por: Wang, Xiaoqi, et al.
Publicado: (2020)

CSF p-tau231: A biomarker for early preclinical Alzheimer?
por: Suárez-Calvet, Marc
Publicado: (2022)

Tackling a difficult question: how do crystals of coordination polymers form?
por: James, Stuart L.
Publicado: (2014)

Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease
por: Vannini, Patrizia, et al.
Publicado: (2020)

Respect the synchrotron beam strength: how to model it, measure it and mitigate it for various scientific fields
por: Helliwell, John R.
Publicado: (2021)

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study
por: Hanseeuw, Bernard J., et al.
Publicado: (2019)

Predicting the Next Superspreader
por: Chavez-Arroyo, Alfredo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lkkg1krfljo8etp807iqv21eds